HES1 oscillations are required for cell cycle re-entry in oestrogen receptor positive breast cancer cells
Preprint
Abstract
Long-term recurrence in breast cancer is driven by reactivation of dormant disseminated tumour cells (DTCs) and remains a major clinical challenge, particularly in oestrogen receptor positive (ER⁺) tumours. This process is underpinned by regulation of the cell cycle machinery that controls quiescence maintenance and exit. HES1, a Notch pathway transcription factor, regulates key cell cycle genes and has been shown to demonstrate protein expression oscillations. Here, we sought to establish whether HES1 oscillations may regulate ER+ cancer cell quiescence and reactivation. To investigate this, we developed a fundamental in vitro model of cell cycle arrest and re-entry based on reversible CDK4/6 inhibition (CDK4/6i) with palbociclib, compatible with quantitative single-cell live-imaging of a knock-in endogenous HES1 reporter. Consistent with earlier findings, HES1 exhibited ∼24-hour protein oscillations in cycling cells demonstrating a reproducible dip in protein expression prior to S-Phase. During CDK4/6i-mediated arrest, the ∼24h HES1 oscillation was lost, HES1 levels were maintained at a moderately higher level and HES1 exhibited smaller dips. Similar changes were observed in unperturbed, spontaneously quiescent cells. Following release from CDK4/6i and cell cycle re- entry, these alterations were reversed and the characteristic G1/S HES1 dip was observed. Preventing this dip at the point of release, by inducibly sustaining HES1 with a Tet-On system, upregulated the cell cycle inhibitor p21, impeded cell cycle re-entry and induced cell death. These findings suggest that manipulating HES1 dynamics could represent a promising therapeutic approach to prevent reactivation of dormant tumour cells. Significance Statement: Breast cancer can recur years after initial treatment due to reactivation of dormant tumour cells. Understanding how these cells exit dormancy is crucial for preventing relapse. We investigated HES1, a transcription factor with rhythmic protein oscillations, and its role in regulating quiescence in oestrogen receptor-positive (ER⁺) breast cancer cells. Using live-cell imaging and a reversible cell cycle arrest model, we show that HES1 dynamics change during dormancy and reactivation, and that disrupting these oscillations prevents cell cycle re-entry and induces cell death. These findings reveal HES1 protein dynamics as a potential therapeutic vulnerability and highlight a novel strategy to target dormant cancer cells to prevent their reactivation.Keywords
This publication has 67 references indexed in Scilit:
- NGN3 oscillatory expression controls the timing of human pancreatic endocrine differentiationDevelopmental Cell, 2025
- Differential cell-cycle control by oscillatory versus sustained Hes1 expression via p21Cell Reports, 2023
- Quiescent cancer cells resist T cell attack by forming an immunosuppressive nicheCell, 2022
- Mammary Development and Breast Cancer: a Notch PerspectiveJournal of Mammary Gland Biology and Neoplasia, 2021
- N-terminal phosphorylation of xHes1 controls inhibition of primary neurogenesis in XenopusBiochemical and Biophysical Research Communications, 2019
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018European Journal of Cancer, 2018
- Ki67 is a Graded Rather than a Binary Marker of Proliferation versus QuiescenceCell Reports, 2018
- Quantitative Cell Cycle Analysis Based on an Endogenous All-in-One Reporter for Cell Tracking and ClassificationCell Reports, 2017
- Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell ActivityCell Reports, 2015
- MicroRNA-9 Modulates Hes1 Ultradian Oscillations by Forming a Double-Negative Feedback LoopCell Reports, 2012